Literature DB >> 10319427

4-(1-benzoylindol-3-yl)butyric acids and FK143: novel nonsteroidal inhibitors of steroid 5 alpha-reductase (II).

K Sawada1, S Okada, P Golden, N Kayakiri, Y Sawada, M Hashimoto, H Tanaka.   

Abstract

A novel series of indolebutyric acids with varying benzoyl substituents were synthesized to develop nonsteroidal inhibitors of steroid 5 alpha-reductase. We previously reported the discovery of a novel nonsteroidal 5 alpha-reductase inhibitor, FR119680, which had an IC50 value of 5.0 nM against the rat prostatic enzyme. However, this compound was not strongly active against the human prostatic enzyme. By further study of the structure-activity relationships we succeeded in producing the strongly active compound, FK143, 4-[3-[3-[bis(4-isobutylphenyl)-methylamino]benzoyl]-1H-indol-1-yl] butyric acid, with an IC50 value of 1.9 nM against the human enzyme. FK143 also has in vivo inhibitory activity against the castrated young rat model and it should therefore be an extremely useful agent for the treatment of benign prostatic hyperplasia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10319427     DOI: 10.1248/cpb.47.481

Source DB:  PubMed          Journal:  Chem Pharm Bull (Tokyo)        ISSN: 0009-2363            Impact factor:   1.645


  1 in total

1.  Various treatment options for benign prostatic hyperplasia: A current update.

Authors:  Alankar Shrivastava; Vipin B Gupta
Journal:  J Midlife Health       Date:  2012-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.